Загрузка...
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30(+) Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
Brentuximab vedotin was reported to be effective and safe against refractory/relapsed Hodgkin lymphoma in cohorts of between 12 to 102 patients. Herein we report our retrospective analysis of the French experience with brentuximab vedotin used alone to treat 240 refractory/relapsed Hodgkin lymphoma...
Сохранить в:
| Опубликовано в: : | Haematologica |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Ferrata Storti Foundation
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5004383/ https://ncbi.nlm.nih.gov/pubmed/26768687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.134213 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|